Wired News – LabCorp Collaborates with Unilabs to Expand Development and Reach of Precision Medicine Capabilities

Stock Monitor: Bio-Rad Laboratories Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Laboratory Corp. of America Holdings (NYSE: LH)(“LabCorp”), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LH as the Company’s latest news hit the wire. On June 01, 2018, the Company announced that it has collaborated with Unilabs, a leading European provider of clinical laboratory testing and medical diagnostic imaging services, to provide expanded global development and delivery of companion diagnostics. Financial terms of the agreement remain undisclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Bio-Rad Laboratories, Inc. (NYSE: BIO-B), which also belongs to the Healthcare sector as the Company Laboratory Corp. of America Holdings. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BIO-B

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Laboratory Corp. of America Holdings most recent news is on our radar >and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=LH

This collaboration broadens the network of laboratories used by biopharmaceutical companies to support companion diagnostic development and commercialization.

Details of Collaboration

The purpose of the collaboration is to expand access to commercialization channels for companion diagnostics in North America and Europe and accelerate the adoption of companion diagnostics. The companies will use globally harmonized processes to simplify the technical, regulatory and clinical complexities associated with these critical assays. The first application of these processes will be in oncology, particularly immuno-oncology.

The collaboration will initially focus on the commercial availability of assays that have been developed and validated both analytically and clinically by LabCorp and Covance, LabCorp’s drug development business.

Collaboration Enables the Companies to Capitalize on the Scientific and Operational Strengths of Companion Diagnostics

David P. King, Chairman and Chief Executive Officer of LabCorp, mentioned that Companion diagnostics are an essential component of precision medicine, enabling physicians to identify the patients who are most likely to benefit from targeted and novel therapies.

David added that with this collaboration, both the companies are capitalizing on the scientific and operational strengths of two leaders in companion diagnostics to benefit biopharmaceutical clients who need global solutions for precision medicine, with the ultimate goal of improving health and improving lives for patients around the world.

Collaboration Addresses the Need for Global Harmonization and Combined Capabilities

Jos Lamers, Chief Executive Officer of Unilabs, stated that the collaboration with LabCorp addresses the need for global harmonization and combined capabilities, including scientific expertise, operational excellence, and timely availability of high-quality companion diagnostic services.

Jos added that the combined ability to bridge the time gaps between development phase and drug approval, and to national reimbursement, by offering a centralized laboratory testing facility, gives the respective customers the advantage of early adoption of their drug.

According to Jos, the intimate knowledge of local testing standards, regulatory, and quality requirements, and navigating logistical challenges will ensure instant access to high-quality testing.

LabCorp’s Latest Collaboration

On May 01, 2018, LabCorp and The Recovery Platform announced a new collaboration to expand access to medication-assisted opioid treatment on a national basis. The Recovery Platform is a unique monitoring tool designed to help primary care physicians address and manage opioid-use disorder patient recovery in a compliant and efficient manner. LabCorp is the exclusive national laboratory integrated within The Recovery Platform, allowing for seamless access to LabCorp’s medication-assisted treatment monitoring services.

About Unilabs

Founded in 1987, Unilabs is one of Europe’s leading suppliers of clinical laboratory testing and medical diagnostic imaging services to private and public healthcare providers, local governments, insurance companies, pharmaceutical companies, and the general public. Unilabs has more than 230 laboratories in 15 countries and 350 customer service locations, and processes more than 188 million diagnostic tests each year.

About Laboratory Corp. of America Holdings

LabCorp, an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory, and end-to-end drug development services. The Company was founded in 1978 and is headquartered in Burlington, North Carolina.

Stock Performance Snapshot

June 04, 2018 – At Monday’s closing bell, Laboratory Corp. of America’s stock slightly climbed 0.35%, ending the trading session at $183.05.

Volume traded for the day: 499.40 thousand shares.

Stock performance in the last month – up 7.90%; previous three-month period – up 5.21%; past twelve-month period – up 29.29%; and year-to-date – up 14.76%

After yesterday’s close, Laboratory Corp. of America’s market cap was at $18.65 billion.

Price to Earnings (P/E) ratio was at 25.47.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 501729